The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study

Bevacizumab was not found to be cost effective at its listed price, based on results from the MAX trial.